Core Areas of Research

Cardiovascular disease

Around 3.5 million Australians are affected by cardiovascular disease. Servier has been at the forefront of cardiovascular research and continues to invest significant resources to finding new pharmaceutical compounds and innovative ways to manage hypertension and cardiovascular disease. Current products include Coversyl (perindopril), Coveram (perindopril/amlodipine) and Coralan (ivabradine)


Type 2 diabetes is expected to become Australia's leading cause of disease burden by 2023. Servier is a major driver of R&D in diabetes and many Australians are treated with Diamicron 60mg MR (gliclazide) for Type 2 diabetes. Research is currently underway into developing new therapies for Australian's with diabetes and hence improved outcomes.


Every 10 minutes, someone is admitted to an Australian hospital with an osteoporotic fracture. Treatment of osteoporosis is also a major focus for Servier research. Spanning more than three decades, research into osteoporosis has meant that doctors can now access a first-in-class agent, Protos (strontium ranelate) to treat osteoporosis in both postmenopausal women and also men.


One in five Australians aged 16-85 years has a mental illness at some time in a 12 month period. In recent years Servier research has invested heavily in neuropharmacology and the treatment of brain disease. In psychopharmacology, research is addressing the three main categories of psychiatric disease: depression, anxiety, and schizophrenia. A first in class agent Valdoxan (agomelatine) is registered for the treatment of major depression, including the prevention of relapse.


Cancer is Australia's leading broad cause of disease burden. In the last 10 years, Servier research has been heavily committed to oncology. The first breakthrough was the introduction of Muphoran (fotemustine), for the treatment of disseminated malignant melanoma.